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MGiulio Marchesini, Nazario Melchionda, Giovanni Apolone, Massimo Cuzzolaro, Edoardo Mannucci,
Francesco Corica, Enzo Grossi, and the QUOVADIS Study Group
besity is a major risk factor for several metabolic diseases, frequently clustering to form the metabolic syndrome, carrying
high risk of cardiovascular mortality. We aimed to assess the prevalence of the metabolic syndrome in treatment-seeking
bese subjects and the potential protective effect of physical activity. A cross-sectional analysis of data from a large Italian
atabase of treatment-seeking obese subjects was performed. The metabolic syndrome was defined according to the criteria
rovisionally set by the National Cholesterol Education Expert Panel on Detection, Evaluation, and Treatment of High Blood
holesterol in Adults, based on waist circumference, fasting glucose, triglyceride (TG) and high-density lipoprotein-choles-
erol (HDL-C) levels, and arterial pressure. Data were available in 1,889 Caucasian subjects, 78% females, from 25 obesity
enters. Minimum criteria for the metabolic syndrome were fulfilled in 53% of cases. The prevalence increased with age and
besity class and was negatively associated with participation in a structured program of physical activity (odds ratio, 0.76;
.58 to 0.99; P  .041), after correction for age, sex, and body mass. The prevalence of cardiovascular disease was higher in
ubjects with the metabolic syndrome. A subset of 12.8% of cases had no metabolic abnormalities. They had a lower
revalence of abdominal obesity and cardiovascular disease. Isolated obesity was significantly associated with physical
ctivity (odds ratio, 1.86; 1.33 to 2.60; P  .0003). Multiple metabolic disorders are present in most obese patients, and their
revalence is lower in physically active subjects. It is time to move towards a more integrated approach and to reconsider
esource allocation to improve lifestyle changes for large-scale control of obesity.2004 Elsevier Inc. All rights reserved.
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SN 1998, the World Health Organization (WHO)1 proposed
the term “Metabolic Syndrome” to define the association of
everal metabolic diseases (obesity, type 2 diabetes, dyslipide-
ia, and hypertension) all contributing to cardiovascular risk.
he syndrome was previously known as syndrome x,2 “deadly
uartet”,3 plurimetabolic syndrome, or as insulin-resistance
yndrome4,5 because of the pathogenic role of reduced insulin
ensitivity. The cut offs of the various components changed
uring the course of years, and other features were included
hyperuricemia, defective fibrinolysis, nonalcoholic steato-
epatitis6), making any epidemiologic survey impossible.
HO criteria were slightly modified in 19997 to comply with
he new classification of hypertension proposed by the WHO-
nternational Society of Hypertension.8 Unfortunately, the cri-
eria proposed by WHO included the assessment of insulin
ensitivity, hence difficult to evaluate and unsuitable for epi-
emiologic purposes. Only recently, the National Cholesterol
ducation Expert Panel on Detection, Evaluation, and Treat-
ent of High Blood Cholesterol in Adults (Adult Treatment
anel III [ATP III])9 provided a working definition of the
etabolic syndrome, which may be easily applied to assess its
revalence in epidemiologic studies.10
The central feature of the metabolic syndrome is obesity11,12;
ts spreading as a worldwide epidemic is a matter of concern in
erms of population health and resource allocation.13 A high
ody fat mass is associated with an elevated cardiovascular
isk,14,15 which increases further in the presence of additional
etabolic disorders16 and is modulated by social factors and
ifestyle habits (smoking, diet, physical activity).17 No system-
tic data are available on the prevalence of the metabolic
yndrome in obese patients when assessed by the well-defined
riteria proposed by ATP III.
The QUOVADIS study (QUality of life in Obesity: eVAlu-
tion and DIsease Surveillance) is a large, observational study
imed at providing a complete picture of obese patients seeking
reatment of obesity at Italian medical centers.18 Several clin-
cal and laboratory data were recorded in patients consecutively
ttending 25 obesity centers. The aim of the present report was
o define the prevalence of the metabolic syndrome in treat-
etabolism, Vol 53, No 4 (April), 2004: pp 435-440ent-seeking obese persons, its possible association with car-
iovascular risk profile, and the putative protective effect of
hysical activity on metabolic disorders.
MATERIALS AND METHODS
atients
During the years 1999 to 2000, 25 Italian centers with specific
nterest in clinical research consecutively enrolled treatment-seeking
bese patients (body mass index [BMI]  30 kg/m2) in an observa-
ional study specifically aimed at measuring the burden of obesity and
ts complications on health-related quality of life and psychologic
istress. The protocol of the study and the main features of patients
ave been previously reported.18 Briefly, the enrolment period was
receded by 2 meetings of the steering committee and by a general
nvestigators’ meeting to decide selection criteria, to agree on data
ollection, and managing of patients. All obese subjects seeking treat-
ent were eligible for the study, provided they were not on active
reatment for obesity at the time of enrolment, were in the age range
etween 20 and 65, agreed to fill a package of self-administered
uestionnaires, and signed an informed consent to participate. History
aking and clinical examination were performed by means of a pre-
efined checklist agreed by all participants. The Case Report Form
ncluded information on civil and educational status, personal and
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436 MARCHESINI ET ALamily history of metabolic and cardiovascular diseases, as well as
revious and current pharmacologic treatment. Recorded data also
omprised cigarette smoking and alcohol consumption and participa-
ion in a structured program of physical activity. Any type of physical
ctivity was considered, including brisk walking, either under super-
ision of an exercise trainer or self-organized, provided patients exer-
ised for a minimum of 30 minutes, at least twice a week. To expedite
andling of data, the study was totally web-based, through an extranet
ystem provided by CINECA (Casalecchio di Reno, Italy), using the
MR (Advanced Multicenter Research) methodology, developed by
INECA as a result of an extensive cooperation of clinicians, statisti-
ians, and informatics. The management of whole data was performed
y standard web-browsers, and the quality level was guaranteed by
pfront quality controls (on client side) and consistency checks (on
erver side).
By December 2001, when the enrolment was closed, the web-based
atabase stored clinical and laboratory data of 1,944 obese subjects of
aucasian origin, but complete data to calculate the prevalence of the
etabolic syndrome were available only in 1,889 cases. Median age
as 45 years. The large majority of subjects were females (n  1,470
77.9%]; 564 [38.2%] postmenopausal). Their average BMI was
8.1  SD 6.4 kg/m2 (range, 30.0 to 82.2). The distribution according
o obesity class was: BMI 30.0 to 34.9, n  725 (38.4%); BMI 35.0 to
9.9, n  534 (28.3%); BMI  40.0, n  630 (33.4%). Coronary heart
nd peripheral vascular diseases were investigated by clinical exami-
ation, history, previous electrocardiogram (ECG) recordings, and
harmacologic treatment; no systematic screening with ECG or Dopp-
er ultrasounds was performed at the time of study.
Diabetes had been previously diagnosed in 12.7% of males (95%
onfidence interval [CI], 9.7 to 16.1) and in 8.3% (7.0 to 9.8) of females
P  .008). Hypertension was treated in 43.5% (38.7 to 48.2) of males
nd 34.5% (32.1 to 36.9) of females (P  .078). Only 6.2% of males
nd 2.4% of females were being treated with fibrates or statins.
In a subset of 712 patients (559 females), 120-minute blood glucose
alues in the course of an oral glucose tolerance test were also avail-
ble.
ethods
Body weight was measured in light clothing and without shoes to the
earest half kilogram. Height was measured to the nearest half centi-
eter. Waist circumference was measured at the nearest half centimeter
t the shortest point below the lower rib margin and the iliac crest,
hereas hip circumference was similarly obtained at the widest point
etween hip and buttocks.
Blood pressure measurements were obtained according to Guidelines
f the International Society of Hypertension.8 Three blood pressure
eadings were obtained at 1-minute intervals, and the second and third
ystolic and diastolic pressure readings were averaged and used in the
Table 1. Prevalence of the Metabolic Syndrome (95%
Metabolic syndrome
Visceral adiposity [waist  102 cm (M),  88 (F)]
Arterial pressure  130/85 mm Hg or antihypertensive treatment
Triglycerides  1.70 mol/L or fibrate-treated
HDL-cholesterol  1.03 mol/L (M),  1.29 mol/L (F)
Fasting blood glucose  6.1 mmol/L or treated for diabetes
NOTE. The SENS, SPEC, and PPV for the diagnosis of the metabol
Abbreviations: SENS, sensitivity, SPEC, specificity; PPV, predictive
*Significantly different from the prevalence reported in male gendnalyses. iPlasma glucose, both in the fasting state and in response to a standard
lucose load, total cholesterol (CHOL), high-density lipoprotein-cho-
esterol (HDL-C), and triglycerides (TG) were measured in individual
enters at the time of enrollment by common standard laboratory
echniques (CHOL, HDL-C plus [2nd generation], and TG assays
Roche Diagnostics, Indianapolis, IN]).
The prevalence of the metabolic syndrome was calculated according
o the ATP III proposal,9 as the presence of 3 or more of the following
riteria: (1) abdominal obesity: waist circumference 102 cm in males
nd  88 cm in females; (2) hypertriglyceridemia:  1.7 mmol/L; (3)
ow HDL-C:  1.03 mmol/L in males and  1.29 mmol/L in females;
4) high blood pressure:  130/85 mm Hg; (5) fasting hyperglycemia
impaired fasting glucose [IFG])  110 mg/dL. In addition, all subjects
ith a previous diagnosis and regularly treated for hypertension, dia-
etes, or hypertriglyceridemia with fibrates were considered to fit the
espective criteria, independently of measured values. In subjects no
onger on active treatment, only measured values were considered.
tatistical Analysis
Differences in individual parameters between groups were analyzed
y Student’s t test or Mann-Whitney test, whenever appropriate. The 2
est was used to compare prevalence between groups. Logistic regres-
ion analysis (both univariate and multivariate) was used to identify
actors significantly associated with the presence of the metabolic
yndrome (dependent variable) after adjustment for age and sex. Par-
icipation in a structured program of physical activity, smoking habits,
nd alcohol consumption were additional independent variables. The
dds ratio (OR), the 95% confidence limits, and P values were calcu-
ated. All analyses were performed on a personal computer and Stat-
iew5 program (ABACUS Concepts, Berkeley, CA.) or SPSS/PC
.0 package (SPSS, Chicago, IL.).
RESULTS
BMI and obesity class distribution were not different be-
ween genders (Table 1). A total of 725 patients had class I
besity (BMI: 30 to 34.9 kg/m2), 534 had class II obesity (35
o 39.9), 630 had class III obesity ( 40). Male patients had
igher fasting and postload glucose, higher TG levels, and
ower HDL-C. Also systolic and diastolic pressure readings
ere higher.
The waist criteria for abdominal obesity were fulfilled in
early all cases without differences between genders. Only 5%
f patients with class I obesity had waist girth below the cut off.
The prevalence of the other features of the metabolic syn-
rome was also very high. Hypertension was the most common
nding; blood pressure levels  130/85 mm Hg were measured
nd Its Individual Features in Obese Patients Studied
Males
n  418)
Females
(n  1,471)
Total No.
Positive
SENS
(%)
SPEC
(%)
PPV
(%)
(52-61) 52 (49-54) 1,001
(91-96) 95 (93-96) 1,788 99 10 55
(74-82) 64 (62-67)* 1,273 89 57 70
(40-50) 26 (24-29)* 577 50 92 87
(27-36) 54 (51-56)* 921 71 77 78
(26-34) 17 (15-19)* 380 36 98 95
drome are also reported.
of positive results.CI) a
(
57
94
78
45
32
30
ic syn
valuen 48.7% of patients without a previous diagnosis of hyperten-
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437OBESITY AND THE METABOLIC SYNDROMEion. Incidentally, blood pressure exceeded normal limits in
7.8% (74.5 to 80.7) of patients with previously diagnosed
ypertension.
At least 1 criterion for the metabolic syndrome was fulfilled
n over 99% of cases (Fig 1); 1,001 patients (53.0%; 95% CI,
0.7 to 55.2) fulfilled 3 or more criteria and could be identified
s having the metabolic syndrome, without differences in rela-
ion to gender (males, 56.7%; females, 51.9; P  .08). The
revalence of the metabolic syndrome increased with increas-
ng BMI (Fig 2, top panel), being 43.6% (40.0 to 47.1) in class
obesity, 51.1% (46.8 to 55.2) in class II, and 65.5% (61.6 to
9.0) in class III (P  .0001). Obesity-related changes were
ore marked in females (2; P  .0001) than in males (P 
Fig 1. Prevalence of positive criteria for the metabolic syndrome
n obese subjects. Closed columns, males; open columns, females.
Fig 2. Prevalence of the metabolic syndrome in obesity according
o obesity class (class I, BMI 30 to 34.9; class II, BMI 35 to 39.9; class
II, BMI > 40) and age. Closed columns, males; open columns, fe-1ales.259). Prevalence also increased with age (Fig 2, bottom panel),
rom 38.8% (34.3 to 43.2) in the age range 35 years to 63.3%
58.1 to 68.0) in the age group 56 to 65 years (P  .022 in
ales and P  .0001 in females).
The practice of regular, structured physical activity was
eported by 14.7% of patients (95% CI, 13.2 to 16.4), without
ifferences in relation to gender (males, 13.6%; females,
5.0%; P  .531, Fisher’s exact test). The median weekly time
pent in physical activity was 2 hours (range, 1 to 14). The
revalence of all criteria for the metabolic syndrome was
educed in these patients (Fig 3). Alcohol consumption was
eported in 20.5% (18.7 to 22.4), cigarette smoking in 22.4%
20.5 to 24.3), more frequently in males (P .0001 v females).
Altered glucose metabolism was the most specific factor
redicting the presence of a metabolic syndrome in obese
ersons (Table 1), followed by increased TG, whereas in-
reased arterial pressure had the highest sensitivity.
At logistic regression analysis, the metabolic syndrome was
ositively associated with age (OR, 1.43; 1.32 to 1.56 per 10
ears; P  .0001), BMI (OR, 1.37; 1.27 to 1.48 per 5 kg/m2;
 .0001), and negatively with participation in a structured
rogram of physical activity (OR, 0.63; 0.49 to 0.81; P 
0004). In multivariate analysis, after correction for age, sex,
nd BMI, cigarette smoking and alcohol consumption were not
ssociated with the metabolic syndrome, whereas structured
hysical activity maintained a negative association (OR, 0.76;
.58 to 0.99; P  .041).
A previous diagnosis of coronary heart disease was reported
n 49 patients. The prevalence was higher in males (5.7%, 95%
I, 3.8 to 8.3 v 1.7%, 1.2 to 2.5 in females; P  .0001).
hirteen males and 13 females reported a previous myocardial
nfarction, 3 males and 3 females a previous coronary bypass.
nly 3 patients reported a peripheral vascular disease treated
y femoral bypass or carotid surgery. The prevalence of car-
iovascular disease (any event) was 4.0% (95% CI, 2.9 to 5.3)
n subjects with the metabolic syndrome and only 1.0% (95%
I, 0.5 to 1.8) in subjects not fitting the criteria of ATP III.
Finally, 241 of 1,889 obese patients (12.8%, 95% CI, 11.3 to
Fig 3. Prevalence of positive criteria for the metabolic syndrome
n obese subjects. Open columns, sedentary cases; closed columns,
ubjects involved in physical activity. TG, triglycerides.4.3) had normal glucose and lipid levels and normal blood
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438 MARCHESINI ET ALressure. Their age and obesity class distribution was signifi-
antly skewed when compared with the total group towards
ounger age (P  .0001) and lower obesity class (P  .0001).
ne hundred and fifty-two patients were less than 45 years old
63%), 131 (54%) belonged to obesity class I, 69 (28%) to
besity class II. Twenty-eight cases (11.6%) had a waist cir-
umference below the ATP III cut off. The prevalence of
ardiovascular disease was low (1.7%, 0.5 to 3.9). In only 10 of
1 (11%), the oral glucose tolerance test was indicative of
mpaired glucose tolerance, compared with a prevalence of im-
aired glucose tolerance or diabetes after glucose load of 27% in
he remaining 621 cases. They were more frequently involved in
tructured physical activity (25% v 13% in subjects with additional
etabolic disorders; P  .0001; Fisher’s exact test).
At logistic regression analysis, isolated obesity was signifi-
antly associated with younger age (OR, 0.70; CI, 0.61 to 0.79
er 10 years; P  .0001), with female sex (OR, 0.69; 0.48 to
.99; P  .041), with lower BMI (OR, 0.67; 0.59 to 0.77; P 
0001), and with physical activity (OR, 2.23; 1.62 to 3.09; P 
0001). At multivariate analysis, the positive association with
hysical activity was maintained after correction for age, gen-
er, and BMI (OR, 1.86; 1.33 to 2.60; P  .0003).
DISCUSSION
The present analysis identifies obesity as a multifaceted
isease in which several metabolic abnormalities contribute to
ncrease cardiovascular risk profile. Our prevalence of the
etabolic syndrome in obesity refers to the specific subgroups
f obese patients seeking treatment at obesity centers. It may be
verestimated when compared with the general obese popula-
ion, because of the referral bias to medical centers, where
atients with complications are more likely to be addressed. On
he other hand, the prevalence might be underestimated when
ompared with subjects treated in cardiology units. The relatively
ow prevalence of cardiovascular disease observed in the present
eries suggests that most patients with coronary heart disease do
ot seek treatment for losing weight at obesity centers.
Another source of error might be the definition of altered
lucose metabolism without considering impaired glucose tol-
rance according to WHO criteria.1 In a large cohort of 1,428
ondiabetic obese subjects, isolated impaired glucose tolerance
as reported in 15% to 20% of cases.19 In the subgroup of the
12 patients submitted to an oral glucose load, the inclusion of
mpaired glucose tolerance as screening criterion increased the
verall prevalence of altered glucose metabolism from 24% to
6% and the final prevalence of the metabolic syndrome from
5% to 58%. In the presence of obesity, altered carbohydrate
etabolism was the most specific metabolic abnormality for
he prediction of the metabolic syndrome, and a correct eval-
ation in obese persons is mandatory. Also ATP III acknowl-
dges the high cardiovascular risk associated with diabetes, and
ts presence is considered to confer a risk equivalent to estab-
ished coronary heart disease and other clinical forms of ath-
rosclerotic disease, although a recent study has challenged this
onclusion.20 The combined effects of the obesity epidemic and
opulation ageing, by increasing the prevalence of diabetes,21
ill end up in a dramatic increase in the prevalence of the
etabolic syndrome and correlated cardiovascular disease in ahe next decades, hence the need for correct assessment of the
opulation at risk.
Hypertension was exceedingly common in our series, but its
ink with the metabolic syndrome was not as strong as the one
f diabetes. The ATP III proposal considers the very strict cut
ff of normal blood pressure,8 a limit that is very frequently
vercome in the general population and very rarely achieved by
reatment in general practice,22,23 and also in hypertension
linics in Italy.24 Hypertension has been associated with insulin
esistance,25 which is considered the pathogenic factor of the
etabolic syndrome.26 However, there is evidence that hyper-
ension is not as strongly linked to the metabolic syndrome as
ther variables,27 although maintaining an independent effect.28
The 2 lipid criteria identified 2 slightly different populations.
hereas the cut off for raised TG was more frequently fulfilled
n males, a reduced HDL was more common in females. A lipid
actor was previously identified as principal component of the
etabolic syndrome in males, but not in the general female
opulation.11 The presence of diabetes, in which lipid levels
ay change according to metabolic control,29 may be an addi-
ional confounding factor. The inclusion of subjects treated
ith statins in the low HDL-C group may be considered inap-
ropriate. However, these patients were a minority, and their
xclusion does not change the results significantly.
Although our population had a low prevalence of cardiovas-
ular disease, data are consistent with the metabolic syndrome
eing associated with a higher prevalence of cardiovascular
vents. Similar data have been obtained in several studies in the
eneral population16,30,31 and also in patients with diabetes,32
hen the prevalence of the syndrome was assessed using the
HO criteria.7 The risk is increased independently of ethnic
rigin.33 Follow-up studies are needed to confirm the retrospec-
ive results we obtained in our Caucasian population.
The most relevant finding of the present cross-sectional
tudy is the negative association of structured physical activity
ith the prevalence of the metabolic syndrome. These data are
n agreement with a recent study in obese women34 and with
ntervention studies on the prevention of diabetes.35-37 They
roved that behavior modifications are achievable and effective
n reducing the risk of diabetes by lifestyle changes. The goal
as achieved by a modest reduction of body weight (7% to
0%) through the combined effects of dietary restriction and
ncreased physical exercise. Per se, physical exercise effec-
ively reduces TG levels and increases HDL-C,38,39 thus de-
reasing the prevalence of features of the metabolic syndrome
t multiple levels. The finding that the protective role of struc-
ured physical activity is maintained after correction for age,
ender, and BMI is in keeping with this consideration. Physical
ctivity does not need to be strenuous and time devoted to
xercise does not need to be prolonged to achieve benefits.40
he median time spent in exercise was only 2 hours per week
n our series, and minimum lifestyle changes are needed to
chieve this goal.
Interestingly, our study also identifies a small group of obese
ersons without metabolic involvement (isolated obesity).
ims41 recently proposed that a subgroup of obese, metaboli-
ally normal subjects really exists, whose uncomplicated obe-
ity is not accompanied by insulin resistance,42 and is not
43ssociated with an increased cardiovascular risk. A few of
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439OBESITY AND THE METABOLIC SYNDROMEhese patients do not fit the criteria of abdominal obesity,
espite a BMI in the obesity range. Follow-up and genetic
tudies in this subset are needed to verify whether this condi-
ion is a temporary one, as age and obesity class dependency
ight suggest, or it stems from a different, potentially protec-
ive genotype. Also in this case, lifestyle changes might be
elevant as preventive or therapeutic measures, as supported by
he close association of isolated obesity with the participation
n structured programs of physical activity, after correction for
besity and personal data.
In summary, our data underline the high prevalence of
etabolic disorders associated with obesity to produce the
etabolic syndrome. This clustering of diseases has clinical
mplications due to the continuing increase of obesity44 and
besity-related diseases45 in western countries. A separate
harmacologic treatment of the different components of the
etabolic syndrome is expensive,46 risky because of interac-
ions, largely ineffective to achieve desired target values, as
lso shown in the present series, and finally, unaffordable by
ny health care system.13 It is time for the medical community
o move towards a more integrated approach and for health care
roviders to reconsider resource allocation to a large scale
ontrol of obesity, based on lifestyle changes. Any intervention
n this area may be extremely cost effective.
APPENDIX A
.1. List of Participants in the QUOVADIS Study
Coordinator: N. Melchionda, Bologna.
Steering Committee: N. Melchionda, G. Marchesini (Univer-
ita` di Bologna), G. Apolone (Istituto di Ricerche Farmaco-dults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
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sogiche “Mario Negri,” Milano), M. Cuzzolaro (Universita` di
oma “La Sapienza”), E. Mannucci (Universita` di Firenze), E.
rossi (BRACCO Imaging Spa, Milano).
List of Participants: S. Avagnina,* L. Ferrero (Torino 1, 100
ases), E.G. Barantani,* E. Molinari,* M.L. Petroni,* R.M.
arsala, A. Compare, S. Hacker (Piancavallo, 157), F. Bel-
ore,* (Catania, 6), F. Caviezel,* B. Ambrosi,* A. Tufano
Milano 1, 56), F. Corica,* A. Corsonello, D. De Domenico
Messina, 80), M. Cuzzolaro,* V. Giancotti, M. Valentini, S.
ntonini (Roma 1, 146), E. Dall’Aglio,* A. Adami (Parma,
4), R. Dalle Grave,* C. Scutari (Garda, 41), G. Del Rio,* M.
ondi, R. Menozzi (Modena 1, 100), G. Fatati,* M. Palazzi
Terni, 53), M.A. Fusco,* M.G. Carbonelli (Roma 2, 54), M.
ennaro,* L. Scaglione, K. Rossin (Sanremo, 73), L. Lucchin,*
. Trovato (Bolzano, 30), G. Marchesini,* L. Baraldi, G.
orlani, S. Natale, N. Villanova (Bologna, 202), A.M. Cicca-
one,* K. Chatzianagnostou (Pisa, 89), R.F. Novi,* A. Trom-
etta, M.A. Seardo, G.F. Alberto (Torino 2, 105), A.E. Ponti-
oli,* A. Saibene, P. Vedani (Milano 2, 69), C. Rotella,* S.
iani, T. Zucchi (Firenze, 91), G. Salvioli,* P. Ventura, L.
orselli (Modena 2, 70), F. Tomasi,* S. Barbieri, E. Scalambra
Ferrara, 150), F. Capani,* E. Vitacolonna, M. Taraborrelli
Chieti, 50), C. Noacco,* C. Taboga, S. Mreule (Udine, 60), E.
errari,* F. Magri (Pavia, 60), P. Beck Peccoz,* P.S. Morpurgo
Milano 3, 53), M. De Rosa, A. Covezzoli, F. Campana (CIN-
CA, Bologna), E. Grossi, G. Rivolta, D. Cerutti (BRACCO
maging spa, Milano).
*Principal Investigator. The number of cases enrolled in each
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